KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Rigel Pharmaceuticals (RIGL) EBIT Margin (2016 - 2025)

Rigel Pharmaceuticals has reported EBIT Margin over the past 15 years, most recently at 33.19% for Q4 2025.

  • Quarterly results put EBIT Margin at 33.19% for Q4 2025, up 428.0% from a year ago — trailing twelve months through Dec 2025 was 42.63% (up 2914.0% YoY), and the annual figure for FY2025 was 42.63%, up 2914.0%.
  • EBIT Margin for Q4 2025 was 33.19% at Rigel Pharmaceuticals, down from 40.91% in the prior quarter.
  • Over the last five years, EBIT Margin for RIGL hit a ceiling of 60.09% in Q2 2025 and a floor of 156.92% in Q1 2022.
  • Median EBIT Margin over the past 5 years was 7.33% (2023), compared with a mean of 18.1%.
  • Peak annual rise in EBIT Margin hit 10900bps in 2022, while the deepest fall reached -20846bps in 2022.
  • Rigel Pharmaceuticals' EBIT Margin stood at 104.94% in 2021, then surged by 104bps to 4.05% in 2022, then soared by 35bps to 5.49% in 2023, then soared by 426bps to 28.92% in 2024, then rose by 15bps to 33.19% in 2025.
  • The last three reported values for EBIT Margin were 33.19% (Q4 2025), 40.91% (Q3 2025), and 60.09% (Q2 2025) per Business Quant data.